我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 Johns Hopkins Medicine, Inc.
相关临床试验
583
48 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
40
6.9%
Available
1
0.2%
已完成
314
53.9%
Enrolling By Invitation
尚未招募
7
1.2%
招募中
66
11.3%
终止
121
20.8%
撤回
33
5.7%
暂无批准数据
- A multi-institutional study found that 42% of ovarian cancer patients who achieved clinical remission after first-line therapy still harbored minimal residual disease (MRD) detectable through second-look laparoscopy. - Patients with surgical MRD showed significantly worse progression-free survival (HR, 2.9) and overall survival (HR, 7.7) compared to those without detectable residual disease. - Advanced spatial transcriptomic and proteomic profiling of MRD samples identified specific druggable targets and biological features like hypoxia signaling and immune evasion. - Circulating tumor DNA (ctDNA) blood tests demonstrated potential as a non-invasive tool for MRD detection, with ctDNA-positive status correlating with inferior survival outcomes.
